• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

No interventions proven to prevent late-life dementia

byCaitlyn HuiandDeepti Shroff Karhade
December 29, 2017
in Chronic Disease, Neurology, Psychiatry, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Pharmacologic treatments had no impact on preventing late-life dementia in patients with normal cognition.

2. Adverse events were increased for several pharmacologic interventions aimed at reducing dementia risk.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Dementia is a significant clinical syndrome, which affects a large proportion of the aging population. Dementia may be caused by several factors, including Alzheimer disease and mild cognitive impairment (MCI). The authors of this study sought to evaluate the current landscape of pharmacologic interventions to prevent or delay cognitive decline in adults with normal cognition. It was observed that there are currently no interventions proven to prevent late-life dementia. This study has several limitations. Of note, the authors were unable to assess the root cause of the insufficient evidence for no treatment, such as whether it is due to inadequate pharmacologic intervention versus study design constraints. Published results of some of the studies may also have been subject to reporting bias.

Click to read the study in the Annals of Internal Medicine

Relevant Reading: Evidence-Based Interventions to Improve Quality of Life for Individuals With Dementia

In-Depth [systematic review]: In total, 51 trials were included in this systematic review. Two reviewers extracted data independently. The reviewers extracted variables related to several primary outcomes, such as cognitive diagnoses of MCI or dementia and cognitive performance assessed by validated instruments. Of the 51 trials included, 1 study suggested that estrogen and estrogen-progesterone treatments increased risk of dementia (low evidence). High-dose raloxifene, statins and cholinesterase inhibitors were not shown to have an effect on reducing the development of dementia in persons of normal cognition. The authors also assessed adverse effects in the trials included in this systematic review. Adverse effects consisted of stroke, coronary heart disease, invasive breast cancer, pulmonary embolism, and venous thromboembolism for various different pharmacologic treatments.

RELATED REPORTS

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Decline in gait speed paired with domain-specific cognition decline may be a useful screening assessment for dementia

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cognitive declinecognitive impairmentdementia
Previous Post

Kidney failure risk equation (KFRE) discriminates risk in children with chronic kidney disease

Next Post

Insufficient evidence for physical activity in preventing late-life dementia

RelatedReports

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 29, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 17, 2022
Chronic Disease

Decline in gait speed paired with domain-specific cognition decline may be a useful screening assessment for dementia

May 31, 2022
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Increased physical activity is a long-term protective factor for dementia

May 19, 2022
Next Post
Reduced gestational weight gain with lifestyle intervention

Insufficient evidence for physical activity in preventing late-life dementia

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease

Reduced mortality with culprit-lesion-only percutaneous coronary intervention for acute myocardial infarction with cardiogenic shock

2 Minute Medicine Physician Press Podcast - December 2017

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.